nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-218-10-139-152nogr-2558Research ArticleГЕПАТОЛОГИЯHEPATOLOGYСистематический анализ взаимосвязей между неалкогольной жировой болезнью печени и перегрузкой тканей железом: перспективные направления применения полипептидной терапииSystematic analysis of the relationship between non-alcoholic fatty liver disease and tissue iron overload: promising areas for the use of polypeptide therapyhttps://orcid.org/0000-0002-2659-7998ТоршинИ. Ю.TorshinI. Yu.noemail@neicon.ruhttps://orcid.org/0000-0002-7663-710XГромоваО. А.GromovaO. A.noemail@neicon.ruhttps://orcid.org/0000-0002-5042-4886БогачеваТ. Е.BogachevaT. E.tatiana.boga4iova@yandex.ruФедеральный исследовательский центр «Информатика и управление» Российской академии наукРоссияFederal Research Center “Computer Science and Control” of Russian Academy of SciencesRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Ивановская государственная медицинская академия» Министерства здравоохранения Российской ФедерацииРоссияIvanovo State Medical AcademyRussian Federation202315032024010139152Copyright © Торшин И.Ю., Громова О.А., Богачева Т.Е., 20242024Торшин И.Ю., Громова О.А., Богачева Т.Е.Torshin I.Y., Gromova O.A., Bogacheva T.E.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2558

Перегрузка железом при неалкогольной жировой болезни печени (НАЖБП) - достаточно частый феномен, которому уделяется крайне мало внимания в клинической практике. Тем не менее, перегрузка железом, приводящая к гемосидерозу (отложение «неперевариваемых» нанодисперсных окислов железа в различных тканях) существенно отягощает НАЖБП, стимулируя усиление хронического воспаления, инсулирезистентности и гемосидероза других органов. В результате, происходит ферроптоз гепатоцитов (апоптоз, вызванный перегрузкой железом и гемосидерозом), что ускоряет трансформацию неалкогольного стеатоза в неалкогольный стеатогепатит (НАСГ) и, в дальнейшем, в цирроз печени. Перегрузка железом утяжеляется на фоне микронутриентных дефицитов и патогенной микробиоты кишечника. В работе представлены результаты систематического анализа данного вопроса, описаны перспективы терапии с использованием микронутриентов и гидролизатов плаценты человека (ГПЧ), способствующих не только регенерации ткани печени, но и нормализации гомеостаза железа.

Iron overload in non-alcoholic fatty liver disease (NAFLD) is a fairly common phenomenon that receives very little attention in clinical practice. However, iron overload, leading to hemosiderosis (deposition of “indigestible” nanodispersed iron oxides in various tissues) significantly aggravates NAFLD, stimulating increased chronic inflammation, insulin resistance and hemosiderosis of other organs. As a result, ferroptosis of hepatocytes occurs (apoptosis caused by iron overload and hemosiderosis), which accelerates the transformation of non-alcoholic steatosis into non-alcoholic steatohepatitis (NASH) and, subsequently, into liver cirrhosis. Iron overload is aggravated by micronutrient deficiencies and pathogenic intestinal microbiota. The paper presents the results of a systematic analysis of this issue, describes the prospects for therapy using micronutrients and human placenta hydrolysates (HPP), which contribute not only to the regeneration of liver tissue, but also to the normalization of iron homeostasis.

перегрузка железомгемосидерозжировая болезнь печенигидролизаты плаценты человекаинтеллектуальный анализ данныхiron overloadhemosiderosisfatty liver diseasehuman placenta hydrolysatesdata miningReferencesCusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). EndocrPract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). EndocrPract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431.Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431.Pădureanu V, Dop D, Drăgoescu AN, Pădureanu R, Mușetescu AE, Nedelcu L. Non-alcoholic fatty liver disease and hematologic manifestations (Review). Exp Ther Med. 2021 Dec;22(6):1355. doi: 10.3892/etm.2021.10790.Pădureanu V, Dop D, Drăgoescu AN, Pădureanu R, Mușetescu AE, Nedelcu L. Non-alcoholic fatty liver disease and hematologic manifestations (Review). Exp Ther Med. 2021 Dec;22(6):1355. doi: 10.3892/etm.2021.10790.May M, Barlow D, Ibrahim R, Houseknecht KL. Mechanisms Underlying Antipsychotic-Induced NAFLD and Iron Dysregulation: A Multi-Omic Approach. Biomedicines. 2022 May 24;10(6):1225. doi: 10.3390/biomedicines10061225.May M, Barlow D, Ibrahim R, Houseknecht KL. Mechanisms Underlying Antipsychotic-Induced NAFLD and Iron Dysregulation: A Multi-Omic Approach. Biomedicines. 2022 May 24;10(6):1225. doi: 10.3390/biomedicines10061225.Kühn JP, Meffert P, Heske C, Kromrey ML, Schmidt CO, Mensel B, Völzke H, Lerch MM, Hernando D, Mayerle J, Reeder SB. Prevalence of Fatty Liver Disease and Hepatic Iron Overload in a Northeastern German Population by Using Quantitative MR Imaging. Radiology. 2017 Sep;284(3):706-716. doi: 10.1148/radiol.2017161228.Kühn JP, Meffert P, Heske C, Kromrey ML, Schmidt CO, Mensel B, Völzke H, Lerch MM, Hernando D, Mayerle J, Reeder SB. Prevalence of Fatty Liver Disease and Hepatic Iron Overload in a Northeastern German Population by Using Quantitative MR Imaging. Radiology. 2017 Sep;284(3):706-716. doi: 10.1148/radiol.2017161228.Honma K, Kirihara S, Nakayama H, Fukuoka T, Ohara T, Kitamori K, Sato I, Hirohata S, Fujii M, Yamamoto S, Ran S, Watanabe S. Selective autophagy associated with iron overload aggravates non-alcoholic steatohepatitis via ferroptosis. Exp Biol Med (Maywood). 2023 Jul;248(13):1112-1123. doi: 10.1177/15353702231191197.Honma K, Kirihara S, Nakayama H, Fukuoka T, Ohara T, Kitamori K, Sato I, Hirohata S, Fujii M, Yamamoto S, Ran S, Watanabe S. Selective autophagy associated with iron overload aggravates non-alcoholic steatohepatitis via ferroptosis. Exp Biol Med (Maywood). 2023 Jul;248(13):1112-1123. doi: 10.1177/15353702231191197.Piperno A, Vergani A, Salvioni A, Trombini P, Vigano M, Riva A, Zoppo A, Boari G, Mancia G. Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. Liver Int. 2004 Oct;24(5):471-6. doi: 10.1111/j.1478-3231.2004.0988.x.Piperno A, Vergani A, Salvioni A, Trombini P, Vigano M, Riva A, Zoppo A, Boari G, Mancia G. Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. Liver Int. 2004 Oct;24(5):471-6. doi: 10.1111/j.1478-3231.2004.0988.x.Lahaye C, Gladine C, Pereira B, Berger J, Chinetti-Gbaguidi G, Laine F, Mazur A, Ruivard M. Does iron overload in metabolic syndrome affect macrophage profile? A case control study. J Trace Elem Med Biol. 2021 Sep;67:126786. doi: 10.1016/j.jtemb.2021.126786.Lahaye C, Gladine C, Pereira B, Berger J, Chinetti-Gbaguidi G, Laine F, Mazur A, Ruivard M. Does iron overload in metabolic syndrome affect macrophage profile? A case control study. J Trace Elem Med Biol. 2021 Sep;67:126786. doi: 10.1016/j.jtemb.2021.126786.Gromova O. A., Torshin I.Yu., Shapovalova Yu.O., Kurtser M. A., Chuchalin A. G. COVID-19 and iron deficiency anemia: relationships of pathogenesis and therapy. Akusherstvo, Ginekologia i Reprodukcia = Obstetrics, Gynecology and Reproduction. 2020;14(5):654-665. (in Russ.) doi: 10.17749/2313-7347/ob.gyn.rep.2020.179. Громова О. А., Торшин И. Ю., Шаповалова Ю. О., Курцер М. А., Чучалин А. Г. COVID-19 и железодефицитная анемия: взаимосвязи патогенеза и терапии. Акушерство, Гинекология Репродукция. 2020;14(5):654-665. doi: 10.17749/2313-7347/ob.gyn.rep.2020.179.Gromova O. A., Torshin I.Yu., Shapovalova Yu.O., Kurtser M. A., Chuchalin A. G. COVID-19 and iron deficiency anemia: relationships of pathogenesis and therapy. Akusherstvo, Ginekologia i Reprodukcia = Obstetrics, Gynecology and Reproduction. 2020;14(5):654-665. (in Russ.) doi: 10.17749/2313-7347/ob.gyn.rep.2020.179. Громова О. А., Торшин И. Ю., Шаповалова Ю. О., Курцер М. А., Чучалин А. Г. COVID-19 и железодефицитная анемия: взаимосвязи патогенеза и терапии. Акушерство, Гинекология Репродукция. 2020;14(5):654-665. doi: 10.17749/2313-7347/ob.gyn.rep.2020.179.Torshin I.Yu., Gromova O. A., Chuchalin A. G., Zhuravlev Yu. I. Chemoreactome screening of the effects of pharmacological drugs on SARS-CoV-2 and human viromes as an information basis for making decisions on the pharmacotherapy of COVID-19. PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2021;14(2):191-211. (in Russ.) doi: 10.17749/2070-4909/farmakoekonomika.2021.078. Торшин И. Ю., Громова О. А., Чучалин А. Г., Журавлев Ю. И. Хемореактомный скрининг воздействия фармакологических препаратов на SARS-CoV-2 и виром человека как информационная основа для принятия решений по фармакотерапии COVID-19. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2021;14(2):191-211. doi: 10.17749/2070-4909/farmakoekonomika.2021.078.Torshin I.Yu., Gromova O. A., Chuchalin A. G., Zhuravlev Yu. I. Chemoreactome screening of the effects of pharmacological drugs on SARS-CoV-2 and human viromes as an information basis for making decisions on the pharmacotherapy of COVID-19. PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2021;14(2):191-211. (in Russ.) doi: 10.17749/2070-4909/farmakoekonomika.2021.078. Торшин И. Ю., Громова О. А., Чучалин А. Г., Журавлев Ю. И. Хемореактомный скрининг воздействия фармакологических препаратов на SARS-CoV-2 и виром человека как информационная основа для принятия решений по фармакотерапии COVID-19. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2021;14(2):191-211. doi: 10.17749/2070-4909/farmakoekonomika.2021.078.Torshin I.Yu., Gromova O. A., Stakhovskaya L. V. et al. Analysis of 19.9 million publications of the PubMed/MEDLINE database using artificial intelligence methods: approaches to summarizing the accumulated data and the «fake news» phenomenon. PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2020;13(2):146-163. (in Russ.) doi: 10.17749/2070-4909/farmakoekonomika.2020.02. @@ Торшин И. Ю., Громова О. А., Стаховская Л. В., Ванчакова Н. П., Галустян А. Н., Кобалава Ж. Д., Гришина Т. Р., Громов А. Н., Иловайская И. А., Коденцова В. М., Калачева А. Г., Лиманова О. А., Максимов В. А., Малявская С. И., Мозговая Е. В., Тапильская Н. И., Рудаков К. В., Семенов В. А. Анализ 19,9 млн публикаций базы данных PubMed/MEDLINE методами искусственного интеллекта: подходы к обобщению накопленных данных и феномен «fake news». ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020;13(2):146-163. doi: 10.17749/2070-4909/farmakoekonomika.2020.02.Torshin I.Yu., Gromova O. A., Stakhovskaya L. V. et al. Analysis of 19.9 million publications of the PubMed/MEDLINE database using artificial intelligence methods: approaches to summarizing the accumulated data and the «fake news» phenomenon. PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2020;13(2):146-163. (in Russ.) doi: 10.17749/2070-4909/farmakoekonomika.2020.02. @@ Торшин И. Ю., Громова О. А., Стаховская Л. В., Ванчакова Н. П., Галустян А. Н., Кобалава Ж. Д., Гришина Т. Р., Громов А. Н., Иловайская И. А., Коденцова В. М., Калачева А. Г., Лиманова О. А., Максимов В. А., Малявская С. И., Мозговая Е. В., Тапильская Н. И., Рудаков К. В., Семенов В. А. Анализ 19,9 млн публикаций базы данных PubMed/MEDLINE методами искусственного интеллекта: подходы к обобщению накопленных данных и феномен «fake news». ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020;13(2):146-163. doi: 10.17749/2070-4909/farmakoekonomika.2020.02.Zhu M, Chen H, Zhou S, Zheng L, Li X, Chu R, Chen W, Wang B, Wang M, Chai Z, Feng W. Iron oxide nanoparticles aggravate hepatic steatosis and liver injury in nonalcoholic fatty liver disease through BMP-SMAD-mediated hepatic iron overload. Nanotoxicology. 2021 Aug;15(6):761-778. doi: 10.1080/17435390.2021.1919329.Zhu M, Chen H, Zhou S, Zheng L, Li X, Chu R, Chen W, Wang B, Wang M, Chai Z, Feng W. Iron oxide nanoparticles aggravate hepatic steatosis and liver injury in nonalcoholic fatty liver disease through BMP-SMAD-mediated hepatic iron overload. Nanotoxicology. 2021 Aug;15(6):761-778. doi: 10.1080/17435390.2021.1919329.Zhang L, Dai X, Wang L, Cai J, Shen J, Shen Y, Li X, Zhao Y. Iron overload accelerated lipid metabolism disorder and liver injury in rats with non-alcoholic fatty liver disease. Front Nutr. 2022 Oct 11;9:961892. doi: 10.3389/fnut.2022.961892.Zhang L, Dai X, Wang L, Cai J, Shen J, Shen Y, Li X, Zhao Y. Iron overload accelerated lipid metabolism disorder and liver injury in rats with non-alcoholic fatty liver disease. Front Nutr. 2022 Oct 11;9:961892. doi: 10.3389/fnut.2022.961892.Crawford DHG, Ross DGF, Jaskowski LA, Burke LJ, Britton LJ, Musgrave N, Briskey D, Rishi G, Bridle KR, Subramaniam VN. Iron depletion attenuates steatosis in a mouse model of non-alcoholic fatty liver disease: Role of iron-dependent pathways. Biochim Biophys Acta Mol Basis Dis. 2021 Jul 1;1867(7):166142. doi: 10.1016/j.bbadis.2021.166142.Crawford DHG, Ross DGF, Jaskowski LA, Burke LJ, Britton LJ, Musgrave N, Briskey D, Rishi G, Bridle KR, Subramaniam VN. Iron depletion attenuates steatosis in a mouse model of non-alcoholic fatty liver disease: Role of iron-dependent pathways. Biochim Biophys Acta Mol Basis Dis. 2021 Jul 1;1867(7):166142. doi: 10.1016/j.bbadis.2021.166142.Shen Y, Li X, Xiong S, Hou S, Zhang L, Wang L, Dai X, Zhao Y. Untargeted metabonomic analysis of non-alcoholic fatty liver disease with iron overload in rats via UPLC/MS. Free Radic Res. 2023 Dec;57(3):195-207. doi: 10.1080/10715762.2023.2226315.Shen Y, Li X, Xiong S, Hou S, Zhang L, Wang L, Dai X, Zhao Y. Untargeted metabonomic analysis of non-alcoholic fatty liver disease with iron overload in rats via UPLC/MS. Free Radic Res. 2023 Dec;57(3):195-207. doi: 10.1080/10715762.2023.2226315.Zhang X, Zuo R, Xiao S, Wang L. Association between iron metabolism and non-alcoholic fatty liver disease: results from the National Health and Nutrition Examination Survey (NHANES 2017-2018) and a controlled animal study. Nutr Metab (Lond). 2022 Dec 13;19(1):81. doi: 10.1186/s12986-022-00715-y.Zhang X, Zuo R, Xiao S, Wang L. Association between iron metabolism and non-alcoholic fatty liver disease: results from the National Health and Nutrition Examination Survey (NHANES 2017-2018) and a controlled animal study. Nutr Metab (Lond). 2022 Dec 13;19(1):81. doi: 10.1186/s12986-022-00715-y.Tan L, Zhou Q, Liu J, Liu Z, Shi R. Association of iron status with non-alcoholic fatty liver disease and liver fibrosis in US adults: a cross-sectional study from NHANES 2017-2018. Food Funct. 2023 Jun 19;14(12):5653-5662. doi: 10.1039/d2fo04082d.Tan L, Zhou Q, Liu J, Liu Z, Shi R. Association of iron status with non-alcoholic fatty liver disease and liver fibrosis in US adults: a cross-sectional study from NHANES 2017-2018. Food Funct. 2023 Jun 19;14(12):5653-5662. doi: 10.1039/d2fo04082d.Hu Z, Li Y, Ma B, Lei S, Wang X. Iron metabolism mediates the relationship between Vitamin C and hepatic steatosis and fibrosis in NAFLD. Front Nutr. 2022 Sep 8;9:952056. doi: 10.3389/fnut.2022.952056.Hu Z, Li Y, Ma B, Lei S, Wang X. Iron metabolism mediates the relationship between Vitamin C and hepatic steatosis and fibrosis in NAFLD. Front Nutr. 2022 Sep 8;9:952056. doi: 10.3389/fnut.2022.952056.Yang HH, Chen GC, Li DM, Lan L, Chen LH, Xu JY, Qin LQ. Serum iron and risk of nonalcoholic fatty liver disease and advanced hepatic fibrosis in US adults. Sci Rep. 2021 May 17;11(1):10387. doi: 10.1038/s41598-021-89991-x.Yang HH, Chen GC, Li DM, Lan L, Chen LH, Xu JY, Qin LQ. Serum iron and risk of nonalcoholic fatty liver disease and advanced hepatic fibrosis in US adults. Sci Rep. 2021 May 17;11(1):10387. doi: 10.1038/s41598-021-89991-x.Eder SK, Feldman A, Strebinger G. et al. Mesenchymal iron deposition is associated with adverse long-term outcome in non-alcoholic fatty liver disease. Liver Int. 2020 Aug;40(8):1872-1882. doi: 10.1111/liv.14503.Eder SK, Feldman A, Strebinger G. et al. Mesenchymal iron deposition is associated with adverse long-term outcome in non-alcoholic fatty liver disease. Liver Int. 2020 Aug;40(8):1872-1882. doi: 10.1111/liv.14503.Yu YC, Luu HN, Wang R, Thomas CE, Glynn NW, Youk AO, Behari J, Yuan JM. Serum Biomarkers of Iron Status and Risk of Hepatocellular Carcinoma Development in Patients with Nonalcoholic Fatty Liver Disease. Cancer Epidemiol Biomarkers Prev. 2022 Jan;31(1):230-235. doi: 10.1158/1055-9965.Yu YC, Luu HN, Wang R, Thomas CE, Glynn NW, Youk AO, Behari J, Yuan JM. Serum Biomarkers of Iron Status and Risk of Hepatocellular Carcinoma Development in Patients with Nonalcoholic Fatty Liver Disease. Cancer Epidemiol Biomarkers Prev. 2022 Jan;31(1):230-235. doi: 10.1158/1055-9965.Qu HJ, Wang L, Zhuang ZJ, Yang WJ, Ding JP, Shi JP. [Studying the correlation between ferritin and non-alcoholic fatty liver disease]. Zhonghua Gan Zang Bing Za Zhi. 2021 Nov 20;29(11):1089-1094. doi: 10.3760/cma.j.cn501113-20200720-00402.Qu HJ, Wang L, Zhuang ZJ, Yang WJ, Ding JP, Shi JP. [Studying the correlation between ferritin and non-alcoholic fatty liver disease]. Zhonghua Gan Zang Bing Za Zhi. 2021 Nov 20;29(11):1089-1094. doi: 10.3760/cma.j.cn501113-20200720-00402.Hagström H, Nasr P, Bottai M, Ekstedt M, Kechagias S, Hultcrantz R, Stål P. Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. Liver Int. 2016 Nov;36(11):1688-1695. doi: 10.1111/liv.13144.Hagström H, Nasr P, Bottai M, Ekstedt M, Kechagias S, Hultcrantz R, Stål P. Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. Liver Int. 2016 Nov;36(11):1688-1695. doi: 10.1111/liv.13144.Messner DJ, Rhieu BH, Kowdley KV. Iron overload causes oxidative stress and impaired insulin signaling in AML-12 hepatocytes. Dig Dis Sci. 2013 Jul;58(7):1899-908. doi: 10.1007/s10620-013-2648-3.Messner DJ, Rhieu BH, Kowdley KV. Iron overload causes oxidative stress and impaired insulin signaling in AML-12 hepatocytes. Dig Dis Sci. 2013 Jul;58(7):1899-908. doi: 10.1007/s10620-013-2648-3.Murotomi K, Tawara H, Sutoh M, Yasunaga M. Iron-accumulating splenocytes may exacerbate non-alcoholic steatohepatitis through the production of proinflammatory cytokines and reactive oxygen species. Exp Biol Med (Maywood). 2022 May;247(10):848-855. doi: 10.1177/15353702221077218.Murotomi K, Tawara H, Sutoh M, Yasunaga M. Iron-accumulating splenocytes may exacerbate non-alcoholic steatohepatitis through the production of proinflammatory cytokines and reactive oxygen species. Exp Biol Med (Maywood). 2022 May;247(10):848-855. doi: 10.1177/15353702221077218.Marti-Aguado D., Ten-Esteve A., Baracaldo-Silva C. M. et al. Pancreatic steatosis and iron overload increases cardiovascular risk in non-alcoholic fatty liver disease. Front Endocrinol (Lausanne). 2023 Aug 3;14:1213441. doi: 10.3389/fendo.2023.1213441.Marti-Aguado D., Ten-Esteve A., Baracaldo-Silva C. M. et al. Pancreatic steatosis and iron overload increases cardiovascular risk in non-alcoholic fatty liver disease. Front Endocrinol (Lausanne). 2023 Aug 3;14:1213441. doi: 10.3389/fendo.2023.1213441.Ittermann T., Khattak R. M., Markus M. R.P. et al. Association between thyroid function and assessment of hepatic fat and iron contents by magnetic resonance imaging. Endocr Connect. 2022 Feb 16;11(2): e210566. doi: 10.1530/EC-21-0566.Ittermann T., Khattak R. M., Markus M. R.P. et al. Association between thyroid function and assessment of hepatic fat and iron contents by magnetic resonance imaging. Endocr Connect. 2022 Feb 16;11(2): e210566. doi: 10.1530/EC-21-0566.Xu J, Sun W, Yang L. Association between iron metabolism and cognitive impairment in older non-alcoholic fatty liver disease individuals: A cross-sectional study in patients from a Chinese center. Medicine (Baltimore). 2019 Nov;98(48): e18189. doi: 10.1097/MD.0000000000018189.Xu J, Sun W, Yang L. Association between iron metabolism and cognitive impairment in older non-alcoholic fatty liver disease individuals: A cross-sectional study in patients from a Chinese center. Medicine (Baltimore). 2019 Nov;98(48): e18189. doi: 10.1097/MD.0000000000018189.Hilton C, Sabaratnam R, Drakesmith H, Karpe F. Iron, glucose and fat metabolism and obesity: an intertwined relationship.Int J Obes (Lond). 2023 Jul;47(7):554-563. doi: 10.1038/s41366-023-01299-0.Hilton C, Sabaratnam R, Drakesmith H, Karpe F. Iron, glucose and fat metabolism and obesity: an intertwined relationship.Int J Obes (Lond). 2023 Jul;47(7):554-563. doi: 10.1038/s41366-023-01299-0.Gromova OA, Torshin IIu, Tetruashvili NK, Gogoleva IV.Sistematicheskii analiz farmakologicheskikh svoistv protein suktsinilatazheleza. Effektivnaia farmakoterapiia. 2018;13:20-9. (in Russ.) Громова О. А., Торшин И. Ю., Тетруашвили Н. К., Гоголева И. В. Систематический анализ фармакологических свойств протеин сукцинилата железа. Эффективная фармакотерапия.2018;13:20-9.Gromova OA, Torshin IIu, Tetruashvili NK, Gogoleva IV.Sistematicheskii analiz farmakologicheskikh svoistv protein suktsinilatazheleza. Effektivnaia farmakoterapiia. 2018;13:20-9. (in Russ.) Громова О. А., Торшин И. Ю., Тетруашвили Н. К., Гоголева И. В. Систематический анализ фармакологических свойств протеин сукцинилата железа. Эффективная фармакотерапия.2018;13:20-9.Sharma R, Zhao W, Zafar Y, Murali AR, Brown KE. Serum hepcidin levels in chronic liver disease: a systematic review and meta-analysis. Clin Chem Lab Med. 2023 Aug 7. doi: 10.1515/cclm-2023-0540.Sharma R, Zhao W, Zafar Y, Murali AR, Brown KE. Serum hepcidin levels in chronic liver disease: a systematic review and meta-analysis. Clin Chem Lab Med. 2023 Aug 7. doi: 10.1515/cclm-2023-0540.Chen J, Li X, Ge C, Min J, Wang F. The multifaceted role of ferroptosis in liver disease. Cell Death Differ. 2022 Mar;29(3):467-480. doi: 10.1038/s41418-022-00941-0.Chen J, Li X, Ge C, Min J, Wang F. The multifaceted role of ferroptosis in liver disease. Cell Death Differ. 2022 Mar;29(3):467-480. doi: 10.1038/s41418-022-00941-0.Lu S, Bennett RG, Kharbanda KK, Harrison-Findik DD. Lack of hepcidin expression attenuates steatosis and causes fibrosis in the liver. World J Hepatol. 2016 Feb 8;8(4):211-25. doi: 10.4254/wjh.v8.i4.211.Lu S, Bennett RG, Kharbanda KK, Harrison-Findik DD. Lack of hepcidin expression attenuates steatosis and causes fibrosis in the liver. World J Hepatol. 2016 Feb 8;8(4):211-25. doi: 10.4254/wjh.v8.i4.211.Boga S, Alkim H, Alkim C, Koksal AR, Bayram M, Yilmaz Ozguven MB, Tekin Neijmann S. The Relationship of Serum Hemojuvelin and Hepcidin Levels with Iron Overload in Nonalcoholic Fatty Liver Disease. J Gastrointestin Liver Dis. 2015 Sep;24(3):293-300. doi: 10.15403/jgld.2014.1121.243.hak.Boga S, Alkim H, Alkim C, Koksal AR, Bayram M, Yilmaz Ozguven MB, Tekin Neijmann S. The Relationship of Serum Hemojuvelin and Hepcidin Levels with Iron Overload in Nonalcoholic Fatty Liver Disease. J Gastrointestin Liver Dis. 2015 Sep;24(3):293-300. doi: 10.15403/jgld.2014.1121.243.hak.Protchenko O., Baratz E., Jadhav S. et al. Iron Chaperone Poly rC Binding Protein 1 Protects Mouse Liver From Lipid Peroxidation and Steatosis. Hepatology. 2021 Mar;73(3):1176-1193. doi: 10.1002/hep.31328.Protchenko O., Baratz E., Jadhav S. et al. Iron Chaperone Poly rC Binding Protein 1 Protects Mouse Liver From Lipid Peroxidation and Steatosis. Hepatology. 2021 Mar;73(3):1176-1193. doi: 10.1002/hep.31328.Zhang H, Zhang E, Hu H. Role of Ferroptosis in Non-Alcoholic Fatty Liver Disease and Its Implications for Therapeutic Strategies. Biomedicines. 2021 Nov 10;9(11):1660. doi: 10.3390/biomedicines9111660.Zhang H, Zhang E, Hu H. Role of Ferroptosis in Non-Alcoholic Fatty Liver Disease and Its Implications for Therapeutic Strategies. Biomedicines. 2021 Nov 10;9(11):1660. doi: 10.3390/biomedicines9111660.Tsurusaki S., Tsuchiya Y., Koumura T. et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis. Cell Death Dis. 2019 Jun 18;10(6):449. doi: 10.1038/s41419-019-1678-y.Tsurusaki S., Tsuchiya Y., Koumura T. et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis. Cell Death Dis. 2019 Jun 18;10(6):449. doi: 10.1038/s41419-019-1678-y.Aslam H., Oza F., Ahmed K., et al. The Role of Red Cell Distribution Width as a Prognostic Marker in Chronic Liver Disease: A Literature Review.Int J Mol Sci. 2023 Feb 9;24(4):3487. doi: 10.3390/ijms24043487.Aslam H., Oza F., Ahmed K., et al. The Role of Red Cell Distribution Width as a Prognostic Marker in Chronic Liver Disease: A Literature Review.Int J Mol Sci. 2023 Feb 9;24(4):3487. doi: 10.3390/ijms24043487.Xu L, Liu W, Bai F, Xu Y, Liang X, Ma C, Gao L. Hepatic Macrophage as a Key Player in Fatty Liver Disease. Front Immunol. 2021 Dec 9;12:708978. doi: 10.3389/fimmu.2021.708978.Xu L, Liu W, Bai F, Xu Y, Liang X, Ma C, Gao L. Hepatic Macrophage as a Key Player in Fatty Liver Disease. Front Immunol. 2021 Dec 9;12:708978. doi: 10.3389/fimmu.2021.708978.Handa P, Thomas S, Morgan-Stevenson V, Maliken BD, Gochanour E, Boukhar S, Yeh MM, Kowdley KV. Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis. J Leukoc Biol. 2019 May;105(5):1015-1026. doi: 10.1002/JLB.3A0318-108R.Handa P, Thomas S, Morgan-Stevenson V, Maliken BD, Gochanour E, Boukhar S, Yeh MM, Kowdley KV. Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis. J Leukoc Biol. 2019 May;105(5):1015-1026. doi: 10.1002/JLB.3A0318-108R.Fujiwara S, Izawa T, Mori M, Atarashi M, Yamate J, Kuwamura M. Dietary iron overload enhances Western diet induced hepatic inflammation and alters lipid metabolism in rats sharing similarity with human DIOS. Sci Rep. 2022 Dec 10;12(1):21414. doi: 10.1038/s41598-022-25838-3.Fujiwara S, Izawa T, Mori M, Atarashi M, Yamate J, Kuwamura M. Dietary iron overload enhances Western diet induced hepatic inflammation and alters lipid metabolism in rats sharing similarity with human DIOS. Sci Rep. 2022 Dec 10;12(1):21414. doi: 10.1038/s41598-022-25838-3.Li H, Hu L, Wang L, Wang Y, Shao M, Chen Y, Wu W, Wang L. Iron Activates cGAS-STING Signaling and Promotes Hepatic Inflammation. J Agric Food Chem. 2022 Feb 23;70(7):2211-2220. doi: 10.1021/acs.jafc.1c06681.Li H, Hu L, Wang L, Wang Y, Shao M, Chen Y, Wu W, Wang L. Iron Activates cGAS-STING Signaling and Promotes Hepatic Inflammation. J Agric Food Chem. 2022 Feb 23;70(7):2211-2220. doi: 10.1021/acs.jafc.1c06681.Gudan A, Kozłowska-Petriczko K, Wunsch E, Bodnarczuk T, Stachowska E. Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023? Nutrients. 2023 Mar 8;15(6):1323. doi: 10.3390/nu15061323.Gudan A, Kozłowska-Petriczko K, Wunsch E, Bodnarczuk T, Stachowska E. Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023? Nutrients. 2023 Mar 8;15(6):1323. doi: 10.3390/nu15061323.Mayneris-Perxachs J., Cardellini M., Hoyles L. et al. Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome. Microbiome. 2021 May 7;9(1):104. doi: 10.1186/s40168-021-01052-7.Mayneris-Perxachs J., Cardellini M., Hoyles L. et al. Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome. Microbiome. 2021 May 7;9(1):104. doi: 10.1186/s40168-021-01052-7.Muzica C. M., Sfarti C., Trifan A. et al. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship. Can J Gastroenterol Hepatol. 2020 Dec 28;2020:6638306. doi: 10.1155/2020/6638306.Muzica C. M., Sfarti C., Trifan A. et al. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship. Can J Gastroenterol Hepatol. 2020 Dec 28;2020:6638306. doi: 10.1155/2020/6638306.Ma W, Jia L, Xiong Q, Feng Y, Du H. The role of iron homeostasis in adipocyte metabolism. Food Funct. 2021 May 21;12(10):4246-4253. doi: 10.1039/d0fo03442h.Ma W, Jia L, Xiong Q, Feng Y, Du H. The role of iron homeostasis in adipocyte metabolism. Food Funct. 2021 May 21;12(10):4246-4253. doi: 10.1039/d0fo03442h.Altamura S, Müdder K, Schlotterer A, Fleming T, Heidenreich E, Qiu R, Hammes HP, Nawroth P, Muckenthaler MU. Iron aggravates hepatic insulin resistance in the absence of inflammation in a novel db/db mouse model with iron overload. Mol Metab. 2021 Sep;51:101235. doi: 10.1016/j.molmet.2021.101235.Altamura S, Müdder K, Schlotterer A, Fleming T, Heidenreich E, Qiu R, Hammes HP, Nawroth P, Muckenthaler MU. Iron aggravates hepatic insulin resistance in the absence of inflammation in a novel db/db mouse model with iron overload. Mol Metab. 2021 Sep;51:101235. doi: 10.1016/j.molmet.2021.101235.Niedermayer F., Su Y., von Krüchten R. et al. Trajectories of glycaemic traits exhibit sex-specific associations with hepatic iron and fat content: Results from the KORA-MRI study. Liver Int. 2023 Oct;43(10):2153-2166. doi: 10.1111/liv.15635.Niedermayer F., Su Y., von Krüchten R. et al. Trajectories of glycaemic traits exhibit sex-specific associations with hepatic iron and fat content: Results from the KORA-MRI study. Liver Int. 2023 Oct;43(10):2153-2166. doi: 10.1111/liv.15635.Wang JW, Jin CH, Ke JF, Ma YL, Wang YJ, Lu JX, Li MF, Li LX. Serum iron is closely associated with metabolic dysfunction-associated fatty liver disease in type 2 diabetes: A real-world study. Front Endocrinol (Lausanne). 2022 Sep 5;13:942412. doi: 10.3389/fendo.2022.942412.Wang JW, Jin CH, Ke JF, Ma YL, Wang YJ, Lu JX, Li MF, Li LX. Serum iron is closely associated with metabolic dysfunction-associated fatty liver disease in type 2 diabetes: A real-world study. Front Endocrinol (Lausanne). 2022 Sep 5;13:942412. doi: 10.3389/fendo.2022.942412.Gromova OA, Torshin IIu, Grishina TR, Tomilova IK. Value of the use of iron preparations and molecular synergists for the prevention and treatment of iron-deficiency anemia in pregnant women.Russian Bulletin of Obstetrician-Gynecologist. 2015;15(4):85-94. (In Russ.) doi: 10.17116/rosakush201515485-94. Громова О. А., Торшин И. Ю., Гришина Т. Р. Значение использования препаратов железа и его молекулярных синергистов для профилактики и лечения железодефицитной анемии у беременных. Российский вестник акушера-гинеколога. 2015;15(4):85-94. doi: 10.17116/rosakush201515485-94.Gromova OA, Torshin IIu, Grishina TR, Tomilova IK. Value of the use of iron preparations and molecular synergists for the prevention and treatment of iron-deficiency anemia in pregnant women.Russian Bulletin of Obstetrician-Gynecologist. 2015;15(4):85-94. (In Russ.) doi: 10.17116/rosakush201515485-94. Громова О. А., Торшин И. Ю., Гришина Т. Р. Значение использования препаратов железа и его молекулярных синергистов для профилактики и лечения железодефицитной анемии у беременных. Российский вестник акушера-гинеколога. 2015;15(4):85-94. doi: 10.17116/rosakush201515485-94.Gromova O. A., Torshin I.Yu., Khadzhidis A. K. Analysis of the molecular mechanisms of the effects of iron (II), copper, manganese in the pathogenesis of iron deficiency anemia. Clinical pharmacology and pharmacoeconomics. 2010, 1: 1-9. (in Russ.) Громова О. А., Торшин И. Ю., Хаджидис А. К. Анализ молекулярных механизмов воздействия железа (II), меди, марганца в патогенезе железодефицитной анемии. Клиническая фармакология и фармакоэкономика, 2010, 1: 1-9.Gromova O. A., Torshin I.Yu., Khadzhidis A. K. Analysis of the molecular mechanisms of the effects of iron (II), copper, manganese in the pathogenesis of iron deficiency anemia. Clinical pharmacology and pharmacoeconomics. 2010, 1: 1-9. (in Russ.) Громова О. А., Торшин И. Ю., Хаджидис А. К. Анализ молекулярных механизмов воздействия железа (II), меди, марганца в патогенезе железодефицитной анемии. Клиническая фармакология и фармакоэкономика, 2010, 1: 1-9.Asprouli E., Kalafati I. P., Sakellari A. et al. Evaluation of Plasma Trace Elements in Different Stages of Nonalcoholic Fatty Liver Disease. Biol Trace Elem Res. 2019 Apr;188(2):326-333. doi: 10.1007/s12011-018-1432-9.Asprouli E., Kalafati I. P., Sakellari A. et al. Evaluation of Plasma Trace Elements in Different Stages of Nonalcoholic Fatty Liver Disease. Biol Trace Elem Res. 2019 Apr;188(2):326-333. doi: 10.1007/s12011-018-1432-9.Morrell A., Tallino S., Yu L., Burkhead J. L. The role of insufficient copper in lipid synthesis and fatty-liver disease. IUBMB Life. 2017 Apr;69(4):263-270. doi: 10.1002/iub.1613.Morrell A., Tallino S., Yu L., Burkhead J. L. The role of insufficient copper in lipid synthesis and fatty-liver disease. IUBMB Life. 2017 Apr;69(4):263-270. doi: 10.1002/iub.1613.Corradini E., Buzzetti E., Dongiovanni P. et al. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. J Hepatol. 2021 Sep;75(3):506-513. doi: 10.1016/j.jhep.2021.03.014.Corradini E., Buzzetti E., Dongiovanni P. et al. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. J Hepatol. 2021 Sep;75(3):506-513. doi: 10.1016/j.jhep.2021.03.014.Xia Z, Hu M, Zheng L, Zheng E, Deng M, Wu J, Sheng X. Assessing whether serum ceruloplasmin promotes non-alcoholic steatohepatitis via regulating iron metabolism. J Med Biochem. 2023 Jan 20;42(1):113-121. doi: 10.5937/jomb0-37597.Xia Z, Hu M, Zheng L, Zheng E, Deng M, Wu J, Sheng X. Assessing whether serum ceruloplasmin promotes non-alcoholic steatohepatitis via regulating iron metabolism. J Med Biochem. 2023 Jan 20;42(1):113-121. doi: 10.5937/jomb0-37597.Wang Q, Zhou D, Wang M, Zhu M, Chen P, Li H, Lu M, Zhang X, Shen X, Liu T, Chen L. A Novel Non-Invasive Approach Based on Serum Ceruloplasmin for Identifying Non-Alcoholic Steatohepatitis Patients in the Non-Diabetic Population. Front Med (Lausanne). 2022 Jun 20;9:900794. doi: 10.3389/fmed.2022.900794.Wang Q, Zhou D, Wang M, Zhu M, Chen P, Li H, Lu M, Zhang X, Shen X, Liu T, Chen L. A Novel Non-Invasive Approach Based on Serum Ceruloplasmin for Identifying Non-Alcoholic Steatohepatitis Patients in the Non-Diabetic Population. Front Med (Lausanne). 2022 Jun 20;9:900794. doi: 10.3389/fmed.2022.900794.Nasr P, Ignatova S, Lundberg P, Kechagias S, Ekstedt M. Low hepatic manganese concentrations in patients with hepatic steatosis - A cohort study of copper, iron and manganese in liver biopsies. J Trace Elem Med Biol. 2021 Sep;67:126772. doi: 10.1016/j.jtemb.2021.126772.Nasr P, Ignatova S, Lundberg P, Kechagias S, Ekstedt M. Low hepatic manganese concentrations in patients with hepatic steatosis - A cohort study of copper, iron and manganese in liver biopsies. J Trace Elem Med Biol. 2021 Sep;67:126772. doi: 10.1016/j.jtemb.2021.126772.Choi J, Choi H, Chung J. Icariin Supplementation Suppresses the Markers of Ferroptosis and Attenuates the Progression of Nonalcoholic Steatohepatitis in Mice Fed a Methionine Choline-Deficient Diet.Int J Mol Sci. 2023 Aug 7;24(15):12510. doi: 10.3390/ijms241512510.Choi J, Choi H, Chung J. Icariin Supplementation Suppresses the Markers of Ferroptosis and Attenuates the Progression of Nonalcoholic Steatohepatitis in Mice Fed a Methionine Choline-Deficient Diet.Int J Mol Sci. 2023 Aug 7;24(15):12510. doi: 10.3390/ijms241512510.Liu H, Yan J, Guan F, Jin Z, Xie J, Wang C, Liu M, Liu J. Zeaxanthin prevents ferroptosis by promoting mitochondrial function and inhibiting the p53 pathway in free fatty acid-induced HepG2 cells. Biochim Biophys Acta Mol Cell Biol Lipids. 2023 Apr;1868(4):159287. doi: 10.1016/j.bbalip.2023.159287.Liu H, Yan J, Guan F, Jin Z, Xie J, Wang C, Liu M, Liu J. Zeaxanthin prevents ferroptosis by promoting mitochondrial function and inhibiting the p53 pathway in free fatty acid-induced HepG2 cells. Biochim Biophys Acta Mol Cell Biol Lipids. 2023 Apr;1868(4):159287. doi: 10.1016/j.bbalip.2023.159287.Guan Q, Wang Z, Hu K, Cao J, Dong Y, Chen Y. Melatonin Ameliorates Hepatic Ferroptosis in NAFLD by Inhibiting ER Stress via the MT2/cAMP/PKA/IRE1 Signaling Pathway.Int J Biol Sci. 2023 Jul 31;19(12):3937-3950. doi: 10.7150/ijbs.85883.Guan Q, Wang Z, Hu K, Cao J, Dong Y, Chen Y. Melatonin Ameliorates Hepatic Ferroptosis in NAFLD by Inhibiting ER Stress via the MT2/cAMP/PKA/IRE1 Signaling Pathway.Int J Biol Sci. 2023 Jul 31;19(12):3937-3950. doi: 10.7150/ijbs.85883.Qi X, Song A, Ma M, Wang P, Zhang X, Lu C, Zhang J, Zheng S, Jin H. Curcumol inhibits ferritinophagy to restrain hepatocyte senescence through YAP/NCOA4 in non-alcoholic fatty liver disease. Cell Prolif. 2021 Sep;54(9): e13107. doi: 10.1111/cpr.13107.Qi X, Song A, Ma M, Wang P, Zhang X, Lu C, Zhang J, Zheng S, Jin H. Curcumol inhibits ferritinophagy to restrain hepatocyte senescence through YAP/NCOA4 in non-alcoholic fatty liver disease. Cell Prolif. 2021 Sep;54(9): e13107. doi: 10.1111/cpr.13107.Gromova O. A., Torshin I.Yu., Chuchalin A. G., Maksimov V. A. Human placenta hydrolysates: from V. P. Filatov to the present day. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(3):434-441. doi: 10.26442/00403660.2022.03.201408. Громова О. А., Торшин И. Ю., Чучалин А. Г., Максимов В. А. Гидролизаты плаценты человека: от В. П. Филатова до наших дней. Терапевтический архив. 2022;94(3):434-441. doi: 10.26442/00403660.2022.03.201408.Gromova O. A., Torshin I.Yu., Chuchalin A. G., Maksimov V. A. Human placenta hydrolysates: from V. P. Filatov to the present day. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(3):434-441. doi: 10.26442/00403660.2022.03.201408. Громова О. А., Торшин И. Ю., Чучалин А. Г., Максимов В. А. Гидролизаты плаценты человека: от В. П. Филатова до наших дней. Терапевтический архив. 2022;94(3):434-441. doi: 10.26442/00403660.2022.03.201408.Gromova O. A., Torshin I.Yu., Minushkin O. N., Dibrova E. A., Karimova I. M., Kustova E. V. [On the effectiveness and molecular mechanisms of action of the drug Laennec in the treatment of pathological conditions of the liver associated with iron deposition in the liver]. Medical journal «Business of Life». 2015;1(1):44-51. Громова О. А., Торшин И. Ю., Минушкин О. Н., Диброва Е. А., Каримова И. М., Кустова Е. В. Об эффективности и молекулярных механизмах действия препарата Лаеннек в лечении патологических состояний печени, связанных с отложением железа в печени. Медицинский журнал «Дело жизни». 2015;1(1): 44-51.Gromova O. A., Torshin I.Yu., Minushkin O. N., Dibrova E. A., Karimova I. M., Kustova E. V. [On the effectiveness and molecular mechanisms of action of the drug Laennec in the treatment of pathological conditions of the liver associated with iron deposition in the liver]. Medical journal «Business of Life». 2015;1(1):44-51. Громова О. А., Торшин И. Ю., Минушкин О. Н., Диброва Е. А., Каримова И. М., Кустова Е. В. Об эффективности и молекулярных механизмах действия препарата Лаеннек в лечении патологических состояний печени, связанных с отложением железа в печени. Медицинский журнал «Дело жизни». 2015;1(1): 44-51.Nazarenko O. A., Gromova O. A., Grishina T. R. et al. Correction by Laennec of chronic iron overload liver, kidneys and brain. Pharmacokinetics and Pharmacodynamics. 2017;(2):39-44. (In Russ.) Назаренко О. А., Громова О. А., Гришина Т. Р., Торшин И. Ю., Демидов В. И., Томилова И. К., Алексахина Е. Л., Гоголева И. В. Коррекция Лаеннеком хронической перегрузки железом печени, почек и головного мозга. Фармакокинетика и Фармакодинамика. 2017;(2):39-44.Nazarenko O. A., Gromova O. A., Grishina T. R. et al. Correction by Laennec of chronic iron overload liver, kidneys and brain. Pharmacokinetics and Pharmacodynamics. 2017;(2):39-44. (In Russ.) Назаренко О. А., Громова О. А., Гришина Т. Р., Торшин И. Ю., Демидов В. И., Томилова И. К., Алексахина Е. Л., Гоголева И. В. Коррекция Лаеннеком хронической перегрузки железом печени, почек и головного мозга. Фармакокинетика и Фармакодинамика. 2017;(2):39-44.Gromova O. A., Torshin I.Yu., Maksimov V. A. et al. Peptides contained in the composition of Laennec that contribute to the treatment of hyperferritinemia and iron overload disorders. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(4):413-425. (In Russ.) doi: 10.17749/2070-4909/farmakoekonomika.2020.070. Громова О. А., Торшин И. Ю., Максимов В. А., Чучалин А. Г., Згода В. Г., Громов А. Н., Тихонова О. В. Пептиды в составе препарата Лаеннек, способствующие устранению гиперферритинемии и перегрузки железом. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020;13(4):413-425. doi: 10.17749/2070-4909/farmakoekonomika.2020.070.Gromova O. A., Torshin I.Yu., Maksimov V. A. et al. Peptides contained in the composition of Laennec that contribute to the treatment of hyperferritinemia and iron overload disorders. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(4):413-425. (In Russ.) doi: 10.17749/2070-4909/farmakoekonomika.2020.070. Громова О. А., Торшин И. Ю., Максимов В. А., Чучалин А. Г., Згода В. Г., Громов А. Н., Тихонова О. В. Пептиды в составе препарата Лаеннек, способствующие устранению гиперферритинемии и перегрузки железом. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020;13(4):413-425. doi: 10.17749/2070-4909/farmakoekonomika.2020.070.Maksimov V. A., Torshin I.Yu., Chuchalin A. G. et al. An experience of using Laennec in patients at high risk of a cytokine storm with COVID-19 and hyperferritinemia. Pul’monologiya. 2020; 30 (5): 587-598. (in Russ.) doi: 10.18093/0869-0189-2020-30-5-587-598. Максимов В. А., Торшин И. Ю., Чучалин А. Г., Лазебник Л. Б., Ткачева О. Н., Стражеско И. Д., Громова О. А. Опыт применения препарата Лаеннек у пациентов с высоким риском развития «цитокинового шторма» на фоне COVID-19 и гиперферритинемии. Пульмонология. 2020; 30 (5): 587-598. doi: 10.18093/0869-0189-2020-30-5-587-598.Maksimov V. A., Torshin I.Yu., Chuchalin A. G. et al. An experience of using Laennec in patients at high risk of a cytokine storm with COVID-19 and hyperferritinemia. Pul’monologiya. 2020; 30 (5): 587-598. (in Russ.) doi: 10.18093/0869-0189-2020-30-5-587-598. Максимов В. А., Торшин И. Ю., Чучалин А. Г., Лазебник Л. Б., Ткачева О. Н., Стражеско И. Д., Громова О. А. Опыт применения препарата Лаеннек у пациентов с высоким риском развития «цитокинового шторма» на фоне COVID-19 и гиперферритинемии. Пульмонология. 2020; 30 (5): 587-598. doi: 10.18093/0869-0189-2020-30-5-587-598.Clinical guidelines [Non-alcoholic fatty liver disease in adults]. (in Russ.) Avalable at: https://cr.minzdrav.gov.ru/schema/748_1. accessed 10/30/2023. Клинические рекомендации «Неалкогольная жировая болезнь печени у взрослых», https://cr.minzdrav.gov.ru/schema/748_1, доступ 30.10.2023.Clinical guidelines [Non-alcoholic fatty liver disease in adults]. (in Russ.) Avalable at: https://cr.minzdrav.gov.ru/schema/748_1. accessed 10/30/2023. Клинические рекомендации «Неалкогольная жировая болезнь печени у взрослых», https://cr.minzdrav.gov.ru/schema/748_1, доступ 30.10.2023.

The authors declare that there are no conflicts of interest present.